EXEL

$70.091.01%0.70

시간 외 거래: 70.13+0.04 +0.06%

Exelixis Inc (EXEL)

Date: O: H: L: C: Vol:

전일 마감가:

$69.39

열려 있는:

$69.53

하루 거래량:

4,636,551

상대 거래량:

1.81

시가총액:

$17.10B

수익:

$2.38B

순이익/손실:

$833.42M

주가수익비율:

23.23

EPS:

$3.02

순현금흐름:

$917.69M

1W 성능:

+7.65%

1M 성능:

+20.04%

6M 성능:

+60.46%

1Y 성능:

+81.25%

1일 변동 폭

$69.15$72.01

1주일 범위

$64.75$72.10

52주 변동 폭

$36.00$72.10

Exelixis Inc 주식 (EXEL) 회사 개요

명칭

Exelixis Inc

부문

Healthcare

산업

Biotechnology

전화

(650) 837-7000

주소

1851 HARBOR BAY PARKWAY, ALAMEDA, CA, USA

직원

1,077

@exelixisinc

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 EXEL에 대한 토론

EXEL vs VRTX, REGN, MRNA, ARGX, ONC 비교

주식	시가총액	매출	순이익	현금흐름	주당 순 이익
EXEL Exelixis Inc	$17.10B	$2.32B	$782.57M	$1.17B	$3.02
VRTX Vertex Pharmaceuticals Inc	$140.94B	$12.59B	$4.41B	$3.80B	$16.87
REGN Regeneron Pharmaceuticals Inc	$99.46B	$16.90B	$4.82B	$3.83B	$41.04
MRNA Moderna Inc	$88.17B	$2.23B	-$3.15B	-$1.24B	-$8.15
ARGX Argen X Se Adr	$55.03B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$40.86B	$6.13B	$655.71M	$1.33B	$4.48

Exelixis Inc 주식(EXEL) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-08-19	개시	BMO Capital Markets	Market Perform
2026-08-06	다운그레이드	Leerink Partners	Outperform → Market Perform
2026-06-25	Resumed	Truist	Hold
2026-01-08	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	다운그레이드	BofA Securities	Neutral → Underperform
2025-11-18	개시	Wolfe Research	Peer Perform
2025-11-03	다운그레이드	Guggenheim	Buy → Neutral
2025-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2025-09-19	Resumed	Barclays	Equal Weight
2025-09-17	Resumed	Barclays	Equal Weight
2025-09-17	개시	Goldman	Buy
2025-07-08	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	업그레이드	Stephens	Equal-Weight → Overweight
2025-02-24	다운그레이드	Wells Fargo	Overweight → Equal Weight
2025-01-27	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	다운그레이드	Oppenheimer	Outperform → Perform
2024-12-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2024-12-17	다운그레이드	BofA Securities	Buy → Neutral
2024-10-16	재확인	RBC Capital Mkts	Outperform
2024-09-19	개시	UBS	Neutral
2024-04-11	다운그레이드	Barclays	Overweight → Equal Weight
2023-12-19	개시	BTIG Research	Buy
2023-12-15	개시	Citigroup	Buy
2023-09-26	개시	H.C. Wainwright	Buy
2023-08-22	재확인	Oppenheimer	Outperform
2023-08-08	개시	SVB Securities	Market Perform
2023-07-11	Resumed	Morgan Stanley	Equal-Weight
2023-05-10	Resumed	Piper Sandler	Overweight
2023-03-09	개시	Wells Fargo	Overweight
2023-01-26	개시	Credit Suisse	Outperform
2022-10-18	개시	JMP Securities	Mkt Outperform
2022-06-24	개시	BMO Capital Markets	Outperform
2021-11-19	개시	Piper Sandler	Overweight
2021-11-03	Resumed	Jefferies	Buy
2021-10-07	개시	Jefferies	Buy
2021-08-06	재확인	H.C. Wainwright	Buy
2021-06-15	개시	H.C. Wainwright	Buy
2021-05-18	Resumed	Goldman	Sell
2021-03-31	개시	Credit Suisse	Outperform
2021-03-12	개시	Wolfe Research	Outperform
2020-03-04	개시	Barclays	Overweight
2020-01-13	개시	SunTrust	Buy
2019-11-13	개시	BofA/Merrill	Buy
2019-03-18	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	개시	Goldman	Neutral
2018-09-10	개시	Morgan Stanley	Underweight
2018-05-11	재확인	Needham	Buy
2017-10-17	재확인	Needham	Buy
2017-10-17	재확인	RBC Capital Mkts	Outperform
2017-10-16	재확인	SunTrust	Buy
2017-09-22	다운그레이드	Leerink Partners	Outperform → Mkt Perform
2017-09-15	개시	RBC Capital Mkts	Outperform
2017-09-12	재확인	Needham	Buy
2017-07-14	개시	SunTrust	Buy
2017-03-31	개시	Needham	Buy
2017-03-16	개시	Oppenheimer	Perform
2017-02-28	다운그레이드	Stifel	Buy → Hold
2016-11-03	개시	Deutsche Bank	Buy
2016-10-10	업그레이드	Piper Jaffray	Neutral → Overweight
2016-09-15	재확인	Stifel	Buy

Exelixis Inc (EXEL) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2026-01-02	2025-01-03	2023-12-29	2022-12-30	2021-12-31
Revenue USD (M)	2,320.13	2,168.70	1,830.21	1,611.06	987.54
Cost of revenue USD (M)	83.70	76.22	72.55	57.91	36.27
Gross profit USD (M)	-	-	1,757.66	1,553.15	951.27
Research and development USD (M)	825.00	910.41	1,044.07	891.81	547.85
Operating expenses USD (M)	1,447.94	1,564.08	1,586.78	1,351.67	841.21
Operating income USD (M)	872.19	604.62	170.89	201.48	110.06
Income before tax USD (M)	-	-	170.89	201.48	130.84
Income tax expense USD (M)	158.64	160.37	49.76	52.07	19.06
Net income USD (M)	782.57	521.27	207.77	182.28	111.78
Basic EPS USD/shares	2.88	1.80	0.65	0.57	0.36
Diluted EPS USD/shares	2.78	1.76	0.65	0.56	0.35
Basic weighted shares shares (M)	271.57	290.03	318.15	321.53	308.27
Diluted weighted shares shares (M)	281.86	296.13	321.46	324.56	318.00
Selling, general and administrative USD (M)	518.73	492.13	542.71	459.86	293.36

Exelixis Inc 주식 (EXEL) 내부자 거래

Beckerle Mary CAug 10 '26
Director
거래
Sale
비용
$53.66
#주식
9,812
가치 ($)
526,512
#주식 총계
16,079
MARY BECKERLEAug 10 '26
Director
거래
Proposed Sale
비용
$53.66
#주식
9,812
가치 ($)
526,496
#주식 총계
0
JACK L WYSZOMIERSKIJun 01 '26
Director
거래
Proposed Sale
비용
$50.55
#주식
3,925
가치 ($)
198,409
#주식 총계
0
Eckhardt Sue GailJun 01 '26
Director
거래
Proposed Sale
비용
$50.87
#주식
9,812
가치 ($)
499,136
#주식 총계
0
Eckhardt Sue GailJun 01 '26
Director
거래
Sale
비용
$50.14
#주식
9,812
가치 ($)
491,974
#주식 총계
16,079
WYSZOMIERSKI JACK LJun 01 '26
Director
거래
Sale
비용
$50.55
#주식
3,925
가치 ($)
198,409
#주식 총계
284,384
Aftab DanaMay 26 '26
EVP, Research and Development
거래
Sale
비용
$50.35
#주식
43,451
가치 ($)
2,187,758
#주식 총계
594,741
DANA T AFTABMay 26 '26
Officer
거래
Proposed Sale
비용
$50.35
#주식
43,451
가치 ($)
2,187,758
#주식 총계
0
PATRICK JOSEPH HALEYMay 20 '26
Officer
거래
Proposed Sale
비용
$49.81
#주식
32,110
가치 ($)
1,599,444
#주식 총계
0
Haley Patrick J.May 20 '26
EVP, Commercial
거래
Sale
비용
$49.81
#주식
32,110
가치 ($)
1,599,399
#주식 총계
357,638

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Beckerle Mary C	Director	Aug 10 '26	Sale	$53.66	9,812	526,512	16,079
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	$53.66	9,812	526,496	0
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	$50.55	3,925	198,409	0
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	$50.87	9,812	499,136	0
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	$50.14	9,812	491,974	16,079
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	$50.55	3,925	198,409	284,384
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	$50.35	43,451	2,187,758	594,741
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	$50.35	43,451	2,187,758	0
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	$49.81	32,110	1,599,444	0
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	$49.81	32,110	1,599,399	357,638

Exelixis Inc 주식(EXEL)의 최신 뉴스

Oct 30, 2026

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

Oct 28, 2026

Oct 27, 2026

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026

Oct 24, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 22, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Oct 22, 2026

Oct 21, 2026

Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance - Finviz

Oct 21, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 21, 2026

Exelixis Inc stock hits all-time high at 63.39 USD By Investing.com - Investing.com Nigeria

Oct 21, 2026

Oct 20, 2026

Exelixis Inc stock hits all-time high at 63.39 USD - Investing.com

Oct 20, 2026

Oct 19, 2026

EXEL Maintained by Citizens -- Price Target Raised to $65.00 - GuruFocus

Oct 19, 2026

Citizens raises Exelixis stock price target to $65 on ESMO data - Investing.com Canada

Oct 19, 2026

Oct 16, 2026

Exelixis, Inc. (1EXEL.MI) stock price, news, quote and history - Yahoo Finance UK

Oct 16, 2026

2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool

Oct 16, 2026

Exelixis, Inc. (0IJO.IL) stock price, news, quote and history - Yahoo Finance UK

Oct 16, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research

Oct 16, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

Oct 16, 2026

Oct 15, 2026

Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade

Oct 15, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Yahoo Finance

Oct 15, 2026

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 15, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Oct 15, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026

Oct 14, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 14, 2026

Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore

Oct 14, 2026

Oct 13, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

Oct 13, 2026

Oct 12, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Oct 12, 2026

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Oct 12, 2026

Oct 10, 2026

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Oct 10, 2026

Oct 09, 2026

Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street

Oct 09, 2026

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

Oct 09, 2026

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Oct 08, 2026

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Oct 08, 2026

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 07, 2026

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance

Oct 07, 2026

Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance

Oct 07, 2026

Is Exelixis Stock Engineered To Make You Money? - Trefis

Oct 07, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 07, 2026

EXEL와(과) 유사한 종목

Exelixis Inc (EXEL)

Exelixis Inc 주식 (EXEL) 회사 개요

EXEL vs VRTX, REGN, MRNA, ARGX, ONC 비교

Exelixis Inc 주식(EXEL) 업그레이드 및 다운그레이드

Exelixis Inc (EXEL) 재무 분석

Exelixis Inc 주식 (EXEL) 내부자 거래

Exelixis Inc 주식(EXEL)의 최신 뉴스

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy - The Motley Fool

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy - Yahoo Finance

Exelixis Rises with Earnings on Tap - FXEmpire

Exelixis, Inc. Estimates – NASDAQ:EXEL - TradingView

Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance - Finviz

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis Inc stock hits all-time high at 63.39 USD By Investing.com - Investing.com Nigeria

Exelixis Inc stock hits all-time high at 63.39 USD - Investing.com

EXEL Maintained by Citizens -- Price Target Raised to $65.00 - GuruFocus

Citizens raises Exelixis stock price target to $65 on ESMO data - Investing.com Canada

Exelixis, Inc. (1EXEL.MI) stock price, news, quote and history - Yahoo Finance UK

2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool

Exelixis, Inc. (0IJO.IL) stock price, news, quote and history - Yahoo Finance UK

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Yahoo Finance

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance

Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance

Is Exelixis Stock Engineered To Make You Money? - Trefis

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

EXEL와(과) 유사한 종목